Oral Therapies

The journey of typical oral medications to the bladder is illustrated in the figure.

Medications enters the digestive system via the gut where they are absorbed into the blood and then transported to the liver where they may be altered by the liver’s metabolism before circulating throughout the body to be picked up by receptive tissues.

The medication then typically gets gradually cleared out of the system by the kidneys and finally dripped into the bladder, an organ that will expel them when the person feels the urge. Given that each person’s body acts in a slightly different way, the end result of this journey is that medications reach the bladder (as well as other parts of the body) in varying dosages with varying degrees of effectiveness. This represents one of the fundamental flaws with treatments currently on the market; a flaw that dtb-instilla rectifies.

Journey to the Bladder

Key Unadressed Need

Urinary tract diseases and disorders are becoming more prevalent due to our aging population. The urinary bladder is rich in molecular receptors and acts as a barrier to the absorption of urinary contents in the bladder cavity. Despite rigorous hygienic standards, about 10% of patients who are catheterized develop urinary tract infections (UTIs).

Previously, a safe and effective means for instilling medications into the bladder has been lacking but UroPharma’s patented direct-to-bladder (dtb) approach enables both therapeutic and prophylactic agents to be delivered directly into the urinary bladder.

UroPharma is focused on treating a broad range of urinary tract disorders with its dtb platform to increase dosing accuracy, improve reliability, and provide safety while reducing side effects associated with oral or intravenous treatments. Not only will this minimize UTI risks associated with extended length of catheter usage but ultimately, through clinician-led dtb administration, enable patients to self-administer treatments comfortably, conveniently, safely, and accurately while improving outcomes and reducing the cost of care.

 

 

 

 

 

 

In the UK, UTIs are the second largest single group of healthcare associated infections extending the average length of hospital stays by ~2.8 days and creating the need for an additional 798,000 beds annually (Health Protection Agency). In the US, UTIs account for 30% of all hospital acquired infections.